Arcturus expands Meiji Seika Pharma partnership with $50 million investment and new mRNA licence

Meiji Seika Pharma has committed $50 million to Arcturus Therapeutics and expanded their mRNA technology partnership through a new licence, strengthening collaboration on RNA medicines and potential pandemic preparedness.
Arcturus Therapeutics announced on 16 November 2026 that Meiji Seika Pharma had agreed to invest $50 million through the purchase of approximately 2.47 million shares at $20.27 each, representing an approximately 80% premium to the relevant historical share-price average and around 7.9% of Arcturus' outstanding shares following the transaction.
The expanded relationship includes an exclusive licence covering an application of ARCT-154 technology in an undisclosed therapeutic area and a separate memorandum of understanding concerning potential pandemic preparedness collaboration in Japan, while the investment is intended to support ARCT-2601 development for ornithine transcarbamylase deficiency and validation of the LUNAR 2.0 mRNA platform.
Field | Content |
Company Receiving Investment | Arcturus Therapeutics |
Investment Partner | Meiji Seika Pharma |
Announcement Date | 16 November 2026 |
Transaction Type | Equity investment and expanded technology licensing collaboration |
Equity Investment | $50 million |
Share Purchase | Approximately 2.47 million shares |
Price Per Share | $20.27 |
Share Price Premium | Approximately 80% to the relevant historical share-price average |
Post-Transaction Ownership | Approximately 7.9% of outstanding shares |
Additional Agreement | Exclusive licence for an application of ARCT-154 technology |
Licensed Therapeutic Area | Undisclosed |
Pandemic Preparedness Arrangement | Separate memorandum of understanding concerning potential collaboration in Japan |
Development Programme Supported | ARCT-2601 for ornithine transcarbamylase deficiency |
Technology Platform Supported | LUNAR 2.0 mRNA platform |
Strategic Focus | RNA medicines development and expanded Japan-linked collaboration |
Agreement Clarification | The pandemic preparedness memorandum is not itself a definitive licensing agreement |
Primary Source | https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-50-million-investment-meiji |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


Comentarios